Additionally, our gain‐of‐function approach involving the systemic administration of exogenous CHI3L1 in mice following myocardial infarction (MI) more closely resembles clinical scenarios, where elevated plasma levels of CHI3L1 are associated with poorer outcomes in patients with MI‐induced heart failure. The gene discussed is CHI3L1; the disease is myocardial infarction.